Saturday, May 27, 2017

Cryoport: Delivering Results

I often refer to Silicon Valley as having a printing press for making money. It literally seems to grow on trees not only down...

Cryoport Revenue Grows by 74%, Driven by Biopharma

Tailwinds' Take: 27 new clients and 14 new trials demonstrates the strength of their competitive positioning in the growing biopharma space. The company is...

Cryoport Added to the Tailwinds Select Portfolio

As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping...

Cryoport Announces Proposed Public Offering of Common Stock

Tailwinds' Take: This transaction will provide the needed cash to see CYRX through to cash-flow positive, an event that will happen in either the...

Cryoport Revenue Continues to Climb, Reporting 53% Growth for the Quarter Ended December 31,...

Tailwind's Take: this is a $2B market potentially and CYRX is the only pure play, fastest growing and best offering in the space. This could...

Cryoport Launches the “CoBRA Index” for a Comprehensive Measure of Activity in the Regenerative...

Tailwind's Take: by publishing this index, investors in CYRX have a unique view into the growth of their industry. Expect this index to remain...

Moffitt Cancer Center Taps Cryoport As Exclusive Cryogenics Logistics Provider

Tailwinds' Take: Moffitt is one of the leading cancer institutes in the US. Their selection of Cryoport is a major endorsement for the company...
Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address